On October 20, 2020 NOXXON Pharma N.V. (Paris:ALNOX) (Euronext Growth Paris: ALNOX), a biotechnology company focused on improving cancer treatments by targeting the tumor microenvironment (TME), reported the collaboration with three additional clinical sites to increase recruitment capacity for the Phase 1/2 brain cancer study of NOX-A12 plus radiotherapy, as a measure to ensure the timely completion of the study under the current challenging conditions posed by the COVID-19 pandemic (Press release, NOXXON, OCT 20, 2020, View Source [SID1234568657]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Along with the hospitals in Mannheim, Essen and Bonn, which have been participating in the recruitment of patients for the study since mid-2019, NOXXON will also collaborate with investigators at three additional hospitals in Leipzig, Münster and Tübingen, Germany.
The clinical Phase 1/2 trial investigates three dose regimens of NOX-A12 (200, 400 and 600 mg/week), each combined with external-beam radiotherapy in newly diagnosed brain cancer patients. Having completed patient recruitment in the first and second dose cohort, all six centers will continue enrolling patients into the highest dose cohort. Top-line data from the study is expected in mid-2021.
"Timely completion of recruitment remains our main focus for this trial. Adding these new clinical sites enables us to increase recruitment capacity and to diversify the geographical distribution of the study in light of the COVID-19 pandemic. We are very pleased to receive the support of three prominent clinical sites in Tübingen, Leipzig and Münster to contribute to this important study," commented Aram Mangasarian, CEO of NOXXON.